Floatz logo

MOGAMULIZUMAB

Lymphoma

Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
(+)-VINCRISTINE
Beth Israel Deaconess Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

MOGAMULIZUMAB is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →